Prevention & lipidsResearch article
Anti-ANGPTL3 Antibody SHR-1918 for Homozygous Familial Hypercholesterolemia
- Nonrandomised clinical trial
- multicentre
- single-arm
- phase 2
- 8 sites in China
- December 19, 2023, to April 2, 2024
Authors' conclusion
Results show that SHR-1918 was associated with a substantial reduction in LDL-C level and favorable safety profile among patients with HoFH taking stable lipid-lowering therapy.
Study context
- Population
- Adults with homozygous familial hypercholesterolemia (HoFH) taking stable lipid-lowering therapy
- Participants
- 26 adults
- Outcome
- Percent change in serum LDL-C from baseline
- Follow-up
- Week 12
Main finding
As reported in the abstract
% change in LDL-C from baseline
Mean % change in low-density lipoprotein cholesterol (LDL-C)
−59.09% (SD, 11.71%; 95% CI, −63.81% to −54.36%)
Further findings
Percent change in LDL-C by HoFH genotype (subgroup) · week 12
- Homozygous
- −61.32%
- Compound heterozygous
- −56.40%
- Double heterozygous
- −72.21%
LDL-C reduction during follow-up · 8-week follow-up
- Reduction observed throughout the entire 8-week follow-up period
Safety
Treatment-emergent adverse events
- ≥1 TEAE, n (%)
- 16 (61.5%)
- Proteinuria (most common), n (%)
- 4 (15.4%)
- Injection site reaction (pain, rash or erythema; both grade 1), n (%)
- 1 (3.8%)
Original publication
Anti-ANGPTL3 Antibody SHR-1918 for Homozygous Familial Hypercholesterolemia. JAMA Cardiol. Published 1 February 2026. doi:10.1001/jamacardio.2025.4878
Summarised from the published abstract; every number is checked against it